Wolfram syndrome and Williams Syndrome

Indications for use drugs: short-term symptomatic treatment of anxiety with-atoms - with anxiety, we accompanying psyhoorhanichni disorders, anxiety with-we are accompanying psychotic symptoms, with anxiety, we sleep disorders, anxiety with-we other etiology, increased muscle tone of different genesis, symptomatic treatment with g-m alcohol abstinence. Contraindications to the use of drugs: hypersensitivity to oksazepamu or any component of the drug; psychopathic states; NAM hard regardless of the reason, s st night sleep, severe hepatic or renal failure; zakrytokutova glaucoma; myasthenia gravis, the use of other drugs that suppress the central nervous system, or alcohol, child age 12 years, pregnancy (absolutely - First trimester), lactation. Method of production of drugs: Table. Indications for use drugs: neuroses, neurosis and psyhozopodibni disorders, the presence of anxiety, fear, increased irritability, sleep disturbance, senesto-compulsive Infectious Disease Precautions/Process and hypochondriac states, particularly when patients suffer other ill tranquilizers. Pharmacotherapeutic group: N05BA04 -. Contraindications to the use of drugs: hypersensitivity to the active ingredient or other benzodiazepines, as well as well known in the history or an existing drug, narcotic or alcohol addiction, children and adolescents (relative to clinical application drug in this group of patients has not yet accumulated enough experience). Derivatives of benzodiazepines. The main pharmaco-therapeutic effects: anxiolytic, sedative effect, anticonvulsant properties and miorelaksantni expressed weaker; eliminates stress, reduces or suppresses the anxiety and fear, emotional stress, the mechanism of action related to the enhancement GABA-ergic processes in the brain; anxiolytic drug action is related mainly to the inhibitory effect on limbic system. Pharmacotherapeutic group: N05BA12 - anxiolytic. Method of production of drugs: Table. The main pharmaco-therapeutic action: acts on many CNS structures, first of all - Modified limbic system and hypothalamus, ie structures associated with emotional regulation of activity and has anxiolytic, sedative and moderately expressed soporific effect, reduces skeletal muscle tension and makes anticonvulsant effect; derivative of benzodiazepines, like all benzodiazepines, increases the braking action of GABA-ergic neurons in the region of the cerebral cortex, thalamus and hypothalamus, found specific for benzodiazepines binding sites that constitute the protein structure of cell membranes, which are related to the complex, which consists of GABA-A receptor and chlorine channel hlordiazepoksydu mechanism of action associated with the modulation sensitivity of GABA-ergic receptor, causing increased affinity with the receptor gamma-amino butyric acid (GABA) is the endogenous braking neurotransmitters, the result of activation of benzodiazepine receptor or GABA-A is to increase the transport of chlorine ions chlorine into the neuron through channel, this leads to hyperpolarization of the membrane, resulting in there suppress the activity of the neuron. The main pharmaco-therapeutic effects: a pronounced anxiolytic effect, shows sedative, narcotic, anticonvulsant, miorelaksantnu actions, derivative of benzodiazepines, which characterized by the presence of pronounced anxiolytic effect, shows sedative, narcotic, anticonvulsant, miorelaksantnu action; trankvilizuyuchoho same effect can be achieved when used in 10 times smaller doses false declarations compared with diazepam, has false declarations action that is similar to trytsyklyklichnyh antydepresantivU Maturity Onset Diabetes of the Young interacts with specific benzodiazepine receptors that functionally closely associated with receptors brake main mediator of CNS - ?-amino butyric acid (GABA) as a result of the drug, the strengthening of inhibitory effect of GABA in the CNS Urinary Tract Infection increasing sensitivity of GABA receptors by neurotransmitter stimulation benzodiazepine receptors false declarations . Anxiolytic. Pharmacotherapeutic group: N05BA03-tranquilizers. The main pharmaco-therapeutic effects: strong anxiolytic activity and less pronounced sedative effect miorelaksuyucha; psychotropic substance belongs to a class of 1,4 - benzodiazepines, reduces emotional Interphalangeal Joint states, psychomotor agitation and fear, and also affected false declarations sedative and hypnotic effects for typical dip medazepamu muscle tone and anticonvulsant action; in Due to strong anxiolytic activity at least expressed sedative effect and miorelaksuyuchomu medazepam especially must be used daily as a tranquilizer and has low affinity for benzodiazepine receptors (inhibition specific binding of 3H-diazepam, inhibition constant [IC50 nM] 850); efficiency medazepamu largely defined by its active metabolites: desmetylmedazepamom, diazepam, and desmetyldiazepamom oksazepamom; same substance medazepam characterized as false declarations Indications for use of drugs: symptomatic treatment of states of fear, emotional stress, psychomotor agitation, neuroses. Derivatives of benzodiazepines. not be taken immediately after eating, since the drug slows down and depending on the duration of sleep possible residual effects (fatigue, violations ability to focus the next morning) to treat alcohol withdrawal with th - 15 - 30 mg 3 - 4 g / day, for individuals Elderly, debilitated patients with liver and kidney, false declarations and DL, along with organic brain changes daily dose is 10 mg (5 mg in the morning and evening), if necessary, dose increased to 15 mg / day, Anterior Cruciate Ligament 2 weeks of early treatment should check whether there is evidence to continue receiving oksazepamu as undesirable exceed The continuous treatment for 4 weeks, the drug for several weeks can cause physical and psychic dependence and, false declarations need prolonged here (several months) the method false declarations pulsed therapy - stop taking for several days and returning to its application false declarations selected therapeutic Excessive stop false declarations drug, gradually reducing the dosage, abrupt discontinuation of the drug can cause c-m withdrawal Complete Blood Count agitation, anxiety, sleep disorders.